Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26997540 | 0.90 | GRM4 (0.38) | P2RY12EGLN1 | |
| SCHEMBL22358360 | 0.90 | RORC (0.43) | — | |
| SCHEMBL30552726 | 0.84 | TUBB4A (0.50) | SMN1; SMN2LDHALMNA | |
| SCHEMBL20116129 | 0.84 | TUBB4A (0.50) | SMN1; SMN2LDHALMNA | |
| SCHEMBL22357989 | 0.82 | LDHA (0.54) | SMN1; SMN2LDHASCD5 | |
| SCHEMBL20116114 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2LDHAP2RY12 | |
| SCHEMBL26999735 | 0.81 | TUBB4A (0.47) | SMN1; SMN2LDHARAB9ALMNA | |
| SCHEMBL20116960 | 0.78 | GPR119 (0.43) | SCD5KMT2A | |
| SCHEMBL22358346 | 0.78 | LDHA (0.40) | SMN1; SMN2LDHATHRAVDRRAB9A | |
| SCHEMBL20116109 | 0.78 | TUBB4A (0.50) | SMN1; SMN2LDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885LDHA 1044/4885THRA 4557/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885LDHA 1044/4885THRA 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.